The second generation of Covid-19 vaccines is unlikely to be included in the Department of Medical Services' procurement pipeline next year while current vaccines remain effective in reducing severe symptoms, says its deputy director-general.
Dr Weerawut Iamsamran said on Tuesday that no evidence has emerged to back claims that bivalent vaccines offer better results than the monovalent platforms widely being used to prevent advanced infection and severe symptoms. "Therefore, the current Covid-19 vaccines can still achieve the goal, especially in reducing severe symptoms of Covid-19," he said.
